Arcturus Therapeutics (NASDAQ:ARCT) is set to announce its earnings results after the market closes on Thursday, August 15th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.15). The business had revenue of $4.35 million during the quarter, compared to the consensus estimate of $3.47 million. Arcturus Therapeutics had a negative return on equity of 132.46% and a negative net margin of 124.59%. On average, analysts expect Arcturus Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Arcturus Therapeutics stock opened at $10.03 on Wednesday. The company has a debt-to-equity ratio of 2.43, a current ratio of 2.51 and a quick ratio of 2.51. The company has a market capitalization of $131.68 million, a P/E ratio of -4.64 and a beta of 2.36. The stock has a fifty day simple moving average of $10.33. Arcturus Therapeutics has a twelve month low of $4.11 and a twelve month high of $15.50.

Several analysts have weighed in on the stock. ValuEngine downgraded shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st. Zacks Investment Research raised shares of Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price target for the company in a research note on Tuesday, July 16th. Chardan Capital set a $18.00 price target on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Thursday, June 20th. Brookline Capital Management reaffirmed a “buy” rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 24th. Finally, HC Wainwright upped their price objective on shares of Arcturus Therapeutics from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the stock. Arcturus Therapeutics presently has an average rating of “Buy” and an average price target of $15.33.

About Arcturus Therapeutics

Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.

Featured Article: What are the economic characteristics of a bear market?

Earnings History for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.